Richard A. Heyman sold $157k of ORIC
director at Oric Pharmaceuticals, Inc.. 13,100 shares at an average of $12.02, traded Jul 24, 2026, filed Jul 28, 2026.
Score components
- +15RoleDirector
- +11Trade size$157k at market
- +10Share of holdings soldSold 29% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001584759-26-000015, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jul 24, 2026 | MOption exercise Common Stock10b5-1 | +3,500 | $1.60 | $5,600 | 45,300 | Jul 28, 2026 |
| Jul 24, 2026 | SOpen-market sale Common Stock10b5-1 | -7,000 | $12.02 | $84k | 38,300 | Jul 28, 2026 |
| Jul 24, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -6,100 | $12.02 | $73k | 206,672 | Jul 28, 2026 |
| Jul 24, 2026 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -3,500 | $0.00 | $0 | 30,200 | Jul 28, 2026 |
Related signals
Other insiders at Oric Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 2Weak | Oric Pharmaceuticals, Inc. | Richard A. Heyman director | $87k 6,700 shares | -16% | |
| 12Weak | Oric Pharmaceuticals, Inc. | Dominic Piscitelli Chief Financial Officer | $181k 13,400 shares | -16% | |
| 0Weak | Oric Pharmaceuticals, Inc. | Dominic Piscitelli Chief Financial Officer | $8,103 600 shares | -1% | |
| 32Weak | Oric Pharmaceuticals, Inc. | Dominic Piscitelli Chief Financial Officer | $1.1M 77,000 shares | -52% | |
| 0Weak | Oric Pharmaceuticals, Inc. | Richard A. Heyman director | $3,600 300 shares | -0% | |
| 18Weak | Oric Pharmaceuticals, Inc. | Dominic Piscitelli Chief Financial Officer | $703k 52,000 shares | -43% | |
| 9Weak | Oric Pharmaceuticals, Inc. | Richard A. Heyman director | $80k 6,700 shares | -15% | |
| 39Weak | Oric Pharmaceuticals, Inc. | Jacob Chacko PRESIDENT AND CEO | $302k 33,374 shares | -5% | |
| 30Weak | Oric Pharmaceuticals, Inc. | Pratik S Multani Chief Medical Officer | $97k 10,720 shares | -14% | |
| 37Weak | Oric Pharmaceuticals, Inc. | Dominic Piscitelli Chief Financial Officer | $97k 10,720 shares | -14% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.